

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Orfadin (nitisinone)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:			
Patient Name:	Supervising Physician:			
Member/Subscriber Number:	Fax:	Phone:		
Date of Birth:	Office Contact:	Thone.		
Group Number:	NPI:	State Lic ID:		
Address:	Address:	0.0.10 2.0 1.2 1		
City, State ZIP:	City, State ZIP:			
Primary Phone:	Specialty/facility name (if applicable)	:		
Drug Name and Strength:				
Directions / SIG:				
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.				
	<u> </u>			
Q1. For what diagnosis is this drug being prescribed (pick one)?				
☐ Hereditary tyrosinemia type 1 (HT-1) ☐ Other				
Q2. Please provide the ICD diagnosis code for the above condition.				
Q3. Is Orfadin being prescribed by a specialist experienced in the treatment of Hereditary Tyrosinemia type 1?				
☐ Yes ☐ No				
Q4. Was the diagnosis of HT-1 confirmed by laboratory or genetic testing (please submit confirmatory clinicals and labs)?				
☐ Yes ☐ No				
Q5. Will Orfadin be used in combination with tyrosine and phenylalanine dietary restrictions?				
☐ Yes ☐ No				
Q6. Is the patient's plasma tyrosine level less than 500 micromole/L?				
☐ Yes ☐ No				



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Orfadin (nitisinone)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:		Prescriber Nam Supervising Ph	
Q7. What is the patient's	current weight and reque	sted dosing regimen?	
Q8. Will the patient be ta	aking Orfadin oral suspens	sion at doses greater tha	n 20 ml?
are they clinically inappr	opriate? (Please explain)	ater than 20 ml, is the pa	atient unable to tolerate Orfadin capsules or
☐ Yes Q10. Additional commer	□ No		
Prese	criber Signature		Date
	_	_	applying the standard review timeframe may to regain maximum function
			uesting providers may speak to a SWHP pharmacist lelp impact the decision on a request before coverage
			This information is intended only for the use of the individual or to any other party. If you are not the intended recipient, you are

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in

error, please notify the sender immediately to arrange for the return of this document